Regavirumab

Regavirumab^?
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	cytomegalovirus glycoprotein B
Clinical data
Identifiers
CAS Registry Number	153101-26-9^N
ATC code	None
Chemical data
N (what is this?) (verify)

Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.^[1]

References

↑ Arizono, H; Sugano, T; Kaida, S; Shibusawa, K; Karasawa, Y; Esumi, Y; Kondo, S; Kiyoki, M (1994). "Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys". Arzneimittel-Forschung 44 (7): 909–13. PMID 7945531.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-vi(r)-")

Human ("-viru-")	Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab Bezlotoxumab

Humanized ("-toxazu-")	Urtoxazumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III